Oscotec Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
53
- Stock Symbol
-
039200
- Investments
-
1
- Share Price
-
$23.75
- (As of Friday Closing)
Oscotec General Information
Description
Oscotec Inc is a research-oriented drug development and biotechnology company have focused on developing synthetic new drugs for diseases such as arthritis and anticancers since its inception. The firm has established a differentiated business model by commercializing various research products and accumulating knowledge obtained during the drug development process into functional materials, related products, and bone graft materials. Based on its business model, its core businesses are: 1) New drug development (synthetic new drugs), 2) Functional materials and related products, and 3) Dental bone graft materials.
Contact Information
Website
www.oscotec.comCorporate Office
- 9th Floor, Building A, Korea Bio-Park
- 700 Daewangpangyo-ro, Bundang-gu
- Seongnam-si, Gyeonggi 13488
- South Korea
Corporate Office
- 9th Floor, Building A, Korea Bio-Park
- 700 Daewangpangyo-ro, Bundang-gu
- Seongnam-si, Gyeonggi 13488
- South Korea
Oscotec Stock Performance
As of 20-Nov-2026, Oscotec’s stock price is $23.75. Its current market cap is $909M with 38.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $23.75 | $24.50 | $18.22 - $44.91 | $909M | 38.3M | 122K | $1.69 |
Oscotec Financials Summary
As of 30-Jun-2026, Oscotec has a trailing 12-month revenue of $99M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 809,401 | 1,139,675 | 569,713 | 602,451 |
| Revenue | 99,350 | 70,154 | 24,924 | 3,787 |
| EBITDA | 67,697 | 37,079 | (1,541) | (26,604) |
| Net Income | 64,814 | 36,780 | 642 | (18,570) |
| Total Assets | 173,155 | 159,619 | 115,941 | 102,879 |
| Total Debt | 11,542 | 10,846 | 9,380 | 4,929 |
Oscotec Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oscotec Patents
Oscotec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260200907-A1 | Crystalline forms of spleen tyrosine kinase inhibitor ski-o-703 | Pending | 06-Jan-2025 | ||
| WO-2026148272-A1 | Crystalline forms of spleen tyrosine kinase inhibitor ski-o-703 | Pending | 06-Jan-2025 | ||
| WO-2024123052-A1 | Fusion comprising anti-tau antibody and peptide and use thereof | Inactive | 08-Dec-2022 | ||
| WO-2020159117-A1 | Oral solid formulation containing pyridopyridine-based hydrochloride and preparation method therefor | Inactive | 01-Feb-2019 | ||
| AU-2019325764-A1 | Crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido(4,3-d)pyrimidin-5(6h)-one hydrochloride and method for preparing same | Active | 23-Aug-2018 | C07D471/04 |
Oscotec Signals
Oscotec Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Oscotec Investments (1)
Oscotec’s most recent deal was a Corporate Asset Purchase with Serin Bioscience (371.9033257 SM Land and 1,956.03 SM Building in Seongnam, South Korea) for . The deal was made on 21-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Serin Bioscience (371.9033257 SM Land and 1,956.03 SM Building in Seongnam, South Korea) | 21-Jul-2021 | Corporate Asset Purchase | Buildings and Property |
Oscotec ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
42.62 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Oscotec Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Genosco | Billerica, MA | 2000 |
Oscotec FAQs
-
When was Oscotec founded?
Oscotec was founded in 1998.
-
Where is Oscotec headquartered?
Oscotec is headquartered in Seongnam-si, South Korea.
-
What is the size of Oscotec?
Oscotec has 53 total employees.
-
What industry is Oscotec in?
Oscotec’s primary industry is Drug Discovery.
-
Is Oscotec a private or public company?
Oscotec is a Public company.
-
What is Oscotec’s stock symbol?
The ticker symbol for Oscotec is 039200.
-
What is the current stock price of Oscotec?
As of 20-Nov-2026 the stock price of Oscotec is $23.75.
-
What is the current market cap of Oscotec?
The current market capitalization of Oscotec is $909M.
-
What is Oscotec’s current revenue?
The trailing twelve month revenue for Oscotec is $99M.
-
What is Oscotec’s annual earnings per share (EPS)?
Oscotec’s EPS for 12 months was $1.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process